['human immunodeficiency virus type 1']
['d/c/f/taf', 'boosted protease inhibitor (bpi)', 'ftc/tdf']

        Inclusion Criteria:

          -  Currently being treated with a stable antiretroviral (ARV) regimen consisting of a
             boosted protease inhibitor (limited to darunavir [DRV] or atazanavir with low-dose
             ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) combined with
             emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) only, for at least 6 consecutive
             months preceding the Screening visit

          -  On-treatment plasma human immunodeficiency virus type 1 ribonucleic acid (HIV-1 RNA)
             concentrations less than (<) 50 copies per milliliter (copies/mL) or HIV-1 RNA
             undetectable by a local HIV-1 RNA test between 12 and 2 months prior to the Screening
             visit and have HIV-1 RNA <50 copies/mL at the Screening visit

          -  A single virologic elevation of greater than or equal to (>=) 50 copies/mL after
             previously reaching viral suppression between 12 and 2 months prior to Screening is
             acceptable, provided a subsequent test prior to Screening was <50 copies/mL

          -  Absence of history of failure on DRV treatment and absence of DRV
             resistance-associated mutations (RAMs), if documented historical genotypes are
             available

          -  Normal electrocardiogram (ECG) at Screening (or if abnormal, determined by the
             Investigator to be not clinically significant)

        Exclusion Criteria:

          -  A new acquired immunodeficiency syndrome (AIDS) - defining condition diagnosed within
             the 30 days prior to Screening

          -  Proven or suspected acute hepatitis within 30 days prior to study entry

          -  Hepatitis C antibody positive; however, participants previously cured of hepatitis C
             virus (HCV) infection, with documented sustained virologic response, that is,
             undetectable HCV RNA 24 weeks after the last dose of HCV treatment, are allowed to
             participate

          -  Hepatitis B surface antigen (HBsAg) positive

          -  Participants with cirrhosis as diagnosed based on local practices
      